Eli Lilly and Company $LLY Shares Purchased by Summit Wealth Group LLC Co.

Summit Wealth Group LLC Co. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 71.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 3,803 shares of the company’s stock after acquiring an additional 1,581 shares during the quarter. Summit Wealth Group LLC Co.’s holdings in Eli Lilly and Company were worth $4,400,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Coastal Bridge Advisors LLC bought a new position in Eli Lilly and Company in the second quarter valued at approximately $2,959,000. Birinyi Associates Inc. increased its position in shares of Eli Lilly and Company by 32.6% during the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after acquiring an additional 359 shares in the last quarter. Mosaic Family Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after acquiring an additional 1,430 shares in the last quarter. Heritage Investors Management Corp increased its position in shares of Eli Lilly and Company by 6.5% during the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock worth $13,624,000 after acquiring an additional 718 shares in the last quarter. Finally, Moran Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after acquiring an additional 9,638 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 18,500 shares of company stock worth $22,970,770. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 0.2%

Eli Lilly and Company stock opened at $1,408.68 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,449.68. The company has a fifty day simple moving average of $1,204.03 and a 200 day simple moving average of $1,095.92. The company has a market cap of $1.33 trillion, a P/E ratio of 45.72, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the previous year, the firm posted $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 35.61 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research report on Friday, October 30th. HSBC increased their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Argus lifted their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday. Guggenheim boosted their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. Finally, Bank of America reaffirmed a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.